PTEN function in normal and neoplastic growth

Cancer Letters

Volumn 241, Issue 2, 2006, Pages 184-196

  Chow, Lionel M L ^a   Baker, Suzanne J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Brain; Endometrium; Glioblastoma; Growth; Prostate; PTEN; Tumor suppressor

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

CARCINOGENESIS; CELL COUNT; CELL MIGRATION; CELL MOTILITY; CELL SIZE; CONGENITAL TUMOR; ENDOMETRIUM CARCINOMA; GENE MUTATION; GLIOBLASTOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE; SHORT SURVEY; TUMOR GROWTH;

ANIMALIA;

EID: 33745888913     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.11.042     Document Type: Review

References (111)

1. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
2. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15 (1997) 356-362
3. Online Mendelian Inheritance in Man, OMIM (TM), Johns Hopkins University (Baltimore, MD), MIM Number: 601728: 6/28/2005, World Wide Web: http://www.ncbi.nlm.nih.gov/omim/
4. Eng C. PTEN: one gene, many syndromes. Hum. Mutat. 22 (2003) 183-198
5. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22 (2004) 2954-2963
6. Maehama T., and Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273 (1998) 13375-13378
7. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
8. Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl Acad. Sci. USA 94 (1997) 9052-9057
9. Neel B.G., Gu H., and Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28 (2003) 284-293
10. Li D.M., and Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57 (1997) 2124-2129
11. Lee J.O., Yang H., Georgescu M.M., Di Cristofano A., Maehama T., Shi Y., et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99 (1999) 323-334
12. Georgescu M.M., Kirsch K.H., Akagi T., Shishido T., and Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc. Natl Acad. Sci. USA 96 (1999) 10182-10187
13. Das S., Dixon J.E., and Cho W. Membrane-binding and activation mechanism of PTEN. Proc. Natl Acad. Sci. USA 100 (2003) 7491-7496
14. Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., and Sellers W.R. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 276 (2001) 48627-48630
15. Torres J., and Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276 (2001) 993-998
16. Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C., et al. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases. J. Biol. Chem. 280 (2005) 28936-28943
17. Lu Y., Yu Q., Liu J.H., Zhang J., Wang H., Koul D., et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J. Biol. Chem. 278 (2003) 40057-40066
18. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004) 117-127
19. Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.J., et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl Acad. Sci. USA 97 (2000) 4233-4238
20. Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., and Lasky L.A. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J. Biol. Chem. 275 (2000) 21477-21485
21. Sumitomo M., Iwase A., Zheng R., Navarro D., Kaminetzky D., Shen R., et al. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 5 (2004) 67-78
22. Gimm O., Perren A., Weng L.P., Marsh D.J., Yeh J.J., Ziebold U., et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am. J. Pathol. 156 (2000) 1693-1700
23. Chung J.H., Ginn-Pease M.E., and Eng C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res. 65 (2005) 4108-4116
24. Lachyankar M.B., Sultana N., Schonhoff C.M., Mitra P., Poluha W., Lambert S., et al. A role for nuclear PTEN in neuronal differentiation. J. Neurosci. 20 (2000) 1404-1413
25. Deleris P., Bacqueville D., Gayral S., Carrez L., Salles J.P., Perret B., and Breton-Douillon M. SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles. J. Biol. Chem. 278 (2003) 38884-38891
26. Liu J.L., Sheng X., Hortobagyi Z.K., Mao Z., Gallick G.E., and Yung W.K. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol. Cell. Biol. 25 (2005) 6211-6224
27. Ginn-Pease M.E., and Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res. 63 (2003) 282-286
28. Ahn J.Y., Liu X., Cheng D., Peng J., Chan P.K., Wade P.A., and Ye K. Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic actions of NGF by inhibiting CAD. Mol. Cell 18 (2005) 435-445
29. Irvine R.F. Nuclear lipid signalling. Nat. Rev. Mol. Cell Biol. 4 (2003) 349-360
30. Puc J., Keniry M., Li H.S., Pandita T.K., Choudhury A.D., Memeo L., et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7 (2005) 193-204
31. Stambolic V., MacPherson D., Sas D., Lin Y., Snow B., Jang Y., et al. Regulation of PTEN transcription by p53. Mol. Cell 8 (2001) 317-325
32. Patel L., Pass I., Coxon P., Downes C.P., Smith S.A., and Macphee C.H. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr. Biol. 11 (2001) 764-768
33. Virolle T., Adamson E.D., Baron V., Birle D., Mercola D., Mustelin T., and de Belle I. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat. Cell Biol. 3 (2001) 1124-1128
34. Kim S., Domon-Dell C., Kang J., Chung D.H., Freund J.N., and Evers B.M. Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop. J. Biol. Chem. 279 (2004) 4285-4291
35. Vasudevan K.M., Gurumurthy S., and Rangnekar V.M. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol. Cell. Biol. 24 (2004) 1007-1021
36. Kozma S.C., and Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. BioEssays 24 (2002) 65-71
37. Kim R.H., Peters M., Jang Y., Shi W., Pintilie M., Fletcher G.C., et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7 (2005) 263-273
38. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998) 29-39
39. Brazil D.P., Yang Z.Z., and Hemmings B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29 (2004) 233-242
40. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
41. Stocker H., Andjelkovic M., Oldham S., Laffargue M., Wymann M.P., Hemmings B.A., and Hafen E. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science 295 (2002) 2088-2091
42. Freeman D.J., Li A.G., Wei G., Li H.H., Kertesz N., Lesche R., et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3 (2003) 117-130
43. Raftopoulou M., Etienne-Manneville S., Self A., Nicholls S., and Hall A. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 303 (2004) 1179-1181
44. Zhou M., Gu L., Findley H.W., Jiang R., and Woods W.G. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res. 63 (2003) 6357-6362
45. Okumura K., Zhao M., DePinho R.A., Furnari F.B., and Cavenee W.K. PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell Cycle 4 (2005) 540-542
46. Kwiatkowski D.J. Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet. 67 (2003) 87-96
47. Goberdhan D.C., Paricio N., Goodman E.C., Mlodzik M., and Wilson C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13 (1999) 3244-3258
48. Huang H., Potter C.J., Tao W., Li D.M., Brogiolo W., Hafen E., et al. PTEN affects cell size, cell proliferation and apoptosis during derosophila eye development. Development 126 (1999) 5365-5372
49. Scanga S.E., Ruel L., Binari R.C., Snow B., Stambolic V., Bouchard D., et al. The conserved PI3'K/PTEN/Akt signaling pathway regulates both cell size and survival in drosophila. Oncogene 19 (2000) 3971-3977
50. Backman S.A., Stambolic V., Suzuki A., Haight J., Elia A., Pretorius J., et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling lhermitte-duclos disease. Nat. Genet. 29 (2001) 396-403
51. Kwon C.H., Zhu X., Zhang J., Knoop L.L., Tharp R., Smeyne R.J., et al. Pten regulates neuronal soma size: a mouse model of lhermitte-duclos disease. Nat. Genet. 29 (2001) 404-411
52. Marino S., Krimpenfort P., Leung C., van der Korput H.A., Trapman J., Camenisch I., et al. PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development 129 (2002) 3513-3522
53. Crackower M.A., Oudit G.Y., Kozieradzki I., Sarao R., Sun H., Sasaki T., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110 (2002) 737-749
54. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 (2003) 209-221
55. Shioi T., Kang P.M., Douglas P.S., Hampe J., Yballe C.M., Lawitts J., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. Eur. Mol. Biol. Org. J. 19 (2000) 2537-2548
56. Kwon C.H., Zhu X., Zhang J., and Baker S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl Acad. Sci. USA 100 (2003) 12923-12928
57. Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3 (2001) 1014-1019
58. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3 (2001) 1009-1013
59. Backman S.A., Ghazarian D., So K., Sanchez O., Wagner K.U., Hennighausen L., et al. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc. Natl Acad. Sci. USA 101 (2004) 1725-1730
60. Suzuki A., Itami S., Ohishi M., Hamada K., Inoue T., Komazawa N., et al. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res. 63 (2003) 674-681
61. Ma X., Ziel-van der Made A.C., Autar B., van der Korput H.A., Vermeij M., van Duijn P., et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res. 65 (2005) 5730-5739
62. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Cristofano A.D., Xiao A., et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1 (2003) 385-396
63. Li G., Robinson G.W., Lesche R., Martinez-Diaz H., Jiang Z., Rozengurt N., et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129 (2002) 4159-4170
64. Kimura T., Suzuki A., Fujita Y., Yomogida K., Lomeli H., Asada N., et al. Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. Development 130 (2003) 1691-1700
65. Horie Y., Suzuki A., Kataoka E., Sasaki T., Hamada K., Sasaki J., et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 113 (2004) 1774-1783
66. Funamoto S., Meili R., Lee S., Parry L., and Firtel R.A. Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. Cell 109 (2002) 611-623
67. Iijima M., and Devreotes P. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell 109 (2002) 599-610
68. Janetopoulos C., Borleis J., Vazquez F., Iijima M., and Devreotes P. Temporal and spatial regulation of phosphoinositide signaling mediates cytokinesis. Dev. Cell 8 (2005) 467-477
69. Fraser M.M., Zhu X., Kwon C.H., Uhlmann E.J., Gutmann D.H., and Baker S.J. Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res. 64 (2004) 7773-7779
70. Groszer M., Erickson R., Scripture-Adams D.D., Lesche R., Trumpp A., Zack J.A., et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294 (2001) 2186-2189
71. Liliental J., Moon S.Y., Lesche R., Mamillapalli R., Li D., Zheng Y., et al. Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr. Biol. 10 (2000) 401-404
72. Gu J., Tamura M., Pankov R., Danen E.H., Takino T., Matsumoto K., and Yamada K.M. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J. Cell Biol. 146 (1999) 389-403
73. Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., and Yamada K.M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280 (1998) 1614-1617
74. Mao J.H., Wu D., Perez-Losada J., Nagase H., DelRosario R., and Balmain A. Genetic interactions between Pten and p53 in radiation-induced lymphoma development. Oncogene 22 (2003) 8379-8385
75. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005) 725-730
76. Chang C.J., Freeman D.J., and Wu H. PTEN regulates Mdm2 expression through the P1 promoter. J. Biol. Chem. 279 (2004) 29841-29848
77. Mayo L.D., Dixon J.E., Durden D.L., Tonks N.K., and Donner D.B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277 (2002) 5484-5489
78. Ali I.U., Schriml L.M., and Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl Cancer Inst. 91 (1999) 1922-1932
79. Goffin A., Hoefsloot L.H., Bosgoed E., Swillen A., and Fryns J.P. PTEN mutation in a family with cowden syndrome and autism. Am. J. Med. Genet. 105 (2001) 521-524
80. Zori R.T., Marsh D.J., Graham G.E., Marliss E.B., and Eng C. Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am. J. Med. Genet. 80 (1998) 399-402
81. Fombonne E., Roge B., Claverie J., Courty S., and Fremolle J. Microcephaly and macrocephaly in autism. J. Autism Dev. Disord. 29 (1999) 113-119
82. Butler M.G., Dasouki M.J., Zhou X.P., Talebizadeh Z., Brown M., Takahashi T.N., et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J. Med. Genet. 42 (2005) 318-321
83. Nicholson K.M., and Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 14 (2002) 381-395
84. Samuels Y., and Velculescu V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3 (2004) 1221-1224
85. To M.D., Perez-Losada J., Mao J.H., and Balmain A. Crosstalk between Pten and Ras signaling pathways in tumor development. Cell Cycle 4 (2005) 1185-1188
86. Kitange G.J., Templeton K.L., and Jenkins R.B. Recent advances in the molecular genetics of primary gliomas. Curr. Opin. Oncol. 15 (2003) 197-203
87. Di Cristofano A., Pesce B., Cordon-Cardo C., and Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19 (1998) 348-355
88. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl Acad. Sci. USA 96 (1999) 1563-1568
89. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8 (1998) 1169-1178
90. Kleihues P., Burger P.C., Collins V.P., Newcomb E.W., Ohgaki H., and Cavenee W.K. Glioblastoma. In: Kleihues P., and Cavanee W.K. (Eds). Pathology and Genetics of Tumours of the Nervous System (2000), IARC Press, Lyon 29-39
91. Behin A., Hoang-Xuan K., Carpentier A.F., and Delattre J.Y. Primary brain tumours in adults. Lancet 361 (2003) 323-331
92. Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., and Parsons R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57 (1997) 4183-4186
93. Zhou X.P., Waite K.A., Pilarski R., Hampel H., Fernandez M.J., Bos C., et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J. Hum. Genet. 73 (2003) 404-411
94. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., Parsons R., Greenberg N., and Ittmann M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl Acad. Sci. USA 98 (2001) 11563-11568
95. Baeza N., Weller M., Yonekawa Y., Kleihues P., and Ohgaki H. PTEN methylation and expression in glioblastomas. Acta Neuropathol. (Berlin) 106 (2003) 479-485
96. She Q.B., Solit D.B., Ye Q., O'Reilly K.E., Lobo J., and Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8 (2005) 287-297
97. Hu X., Pandolfi P.P., Li Y., Koutcher J.A., Rosenblum M., and Holland E.C. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7 (2005) 356-368
98. Xiao A., Yin C., Yang C., Di Cristofano A., Pandolfi P.P., and Van Dyke T. Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res. 65 (2005) 5172-5180
99. Abate-Shen C., and Shen M.M. Molecular genetics of prostate cancer. Genes Dev. 14 (2000) 2410-2434
100. DeMarzo A.M., Nelson W.G., Isaacs W.B., and Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet 361 (2003) 955-964
101. Stambolic V., Tsao M.S., Macpherson D., Suzuki A., Chapman W.B., and Mak T.W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 60 (2000) 3605-3611
102. Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M., and Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl Acad. Sci. USA 99 (2002) 2884-2889
103. Abate-Shen C., Banach-Petrosky W.A., Sun X., Economides K.D., Desai N., Gregg J.P., et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 63 (2003) 3886-3890
104. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., and Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27 (2001) 222-224
105. You M.J., Castrillon D.H., Bastian B.C., O'Hagan R.C., Bosenberg M.W., Parsons R., et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl Acad. Sci. USA 99 (2002) 1455-1460
106. Bayascas J.R., Leslie N.R., Parsons R., Fleming S., and Alessi D.R. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr. Biol. 15 (2005) 1839-1846
107. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10 (2004) 594-601
108. Goswami A., Burikhanov R., de Thonel A., Fujita N., Goswami M., Zhao Y., et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol. Cell 20 (2005) 33-44
109. Ellenson L.H., and Wu T.C. Focus on endometrial and cervical cancer. Cancer Cell 5 (2004) 533-538
110. Wang H., Douglas W., Lia M., Edelmann W., Kucherlapati R., Podsypanina K., et al. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Am. J. Pathol. 160 (2002) 1481-1486
111. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353 (2005) 2012-2024